Lifesprout
Company

Last deal

$28.5M

Amount

Series A

Stage

27.04.2020

Date

4

all rounds

$35.8M

Total amount

General

About Company
LifeSprout develops synthetic soft tissue substitutes for aesthetic and reconstructive medicine.

Industry

Sector :

Subsector :

founded date

01.01.2015

Number of employees

Company Type

For Profit

Last funding type

Series A

IPO status

Private

Description

The company's products are designed to regrow human tissue, allowing doctors to repair soft tissue damage caused by trauma, aging, surgery, cancer, and metabolic disease. LifeSprout's revolutionary platform uses breakthroughs in materials science to create products that mimic the body's own tissues, resulting in enhanced form and function with minimal downtime and excellent results for millions of patients each year.
Contacts